Breaking News Instant updates and real-time market news.

SHOO

Steven Madden

$37.15

-0.1 (-0.27%)

, ILMN

Illumina

$160.00

-1.01 (-0.63%)

10:14
02/27/17
02/27
10:14
02/27/17
10:14

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Steven Madden (SHOO) upgraded to Buy from Neutral at B. Riley by analyst Jeff Van Sinderen, who said last week's footwear show and latest channel checks underscore the company's potential for growth. 2. Illumina (ILMN) upgraded to Buy from Hold at Evercore ISI by analyst Ross Muken following customer checks that lead him to above consensus revenue forecasts. Muken believes Illumina will sell 750-1,300 NovaSeq boxes over the next several years as sequencing enters a new era of utility. 3. Carnival (CCL) upgraded Buy from Hold by Argus analyst John Staszak, who now believes that "continued " improvement in demand for cruises will improve the company's earnings and margins. 4. Cempra (CEMP) upgraded to Buy at Roth Capital by analyst Michael Higgins after the company announced positive Phase 3 results in the first of two skin infection studies with Taksta, and ahead of bone data in 2017. The analyst also raised his price target on the shares to $8 from $2.50. 5. Unilever (UN) upgraded to Neutral from Underperform at BofA Merrill Lynch by analyst David Hayes, citing valuation and his belief that the strategic review could accelerate margin development targets over the next 4 years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

SHOO

Steven Madden

$37.15

-0.1 (-0.27%)

ILMN

Illumina

$160.00

-1.01 (-0.63%)

CCL

Carnival

$55.97

-0.06 (-0.11%)

CEMP

Cempra

$4.05

0.9 (28.57%)

UN

Unilever; also tag UL

$47.36

0.45 (0.96%)

UL

Unilever; also tag UN

$47.52

0.4 (0.85%)

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 01

    Apr

SHOO Steven Madden
$37.15

-0.1 (-0.27%)

01/31/17
SBSH
01/31/17
UPGRADE
Target $40
SBSH
Buy
Steven Madden upgraded to Buy from Neutral at Citi
Citi analyst Corinna Van der Ghinst upgraded Steven Madden to Buy saying a stronger fashion cycle and product momentum, along with "clean" inventories and "best-in-class" execution, make for a "strong setup" going into 2017. The analyst expects Steven Madden to gain share in a challenging retail environment and keeps a $40 price target for the shares.
02/23/17
PIPR
02/23/17
UPGRADE
Target $41
PIPR
Overweight
Steven Madden upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Erinn Murphy upgraded Steven Madden to Overweight on expectations the company can continue outperforming peers in 2017. Following meetings with management, the analyst believes Steven Madden is executing well on fashion and can exceed consensus estimates. Murphy raised her price target for the shares to $41 from $38.
02/27/17
RILY
02/27/17
UPGRADE
Target $45
RILY
Buy
Steven Madden upgraded to Buy from Neutral at B. Riley
B. Riley analyst Jeff Van Sinderen upgraded Steven Madden to Buy and raised his price target for the shares to $45 from $40. Last week's footwear show and latest channel checks underscore the company's potential for growth, Van Sinderen tells investors in a research note.
02/24/17
ADAM
02/24/17
NO CHANGE
Target $45
ADAM
Buy
Steven Madden price target raised to $45 from $40 at Canaccord
Canaccord analyst Camilo Lyon raised his price target on Steven Madden to $45 from $40 following meetings with management. The analyst sees multiple trends spurring a strong spring season and sees the company as the only one in the firm's coverage that can continue to thrive in the challenged retail landscape because its supply model is geared to respond in near-real time to changing consumer tastes. Lyon reiterated his Buy rating on Steven Madden shares.
ILMN Illumina
$160.00

-1.01 (-0.63%)

01/20/17
COWN
01/20/17
NO CHANGE
Target $175
COWN
Outperform
Illumina price target raised to $175 from $150 at Cowen
Cowen analyst Doug Schenkel raised his price target on Illumina to $175 from $150 to reflect the company's guidance and initial channel checks subsequent to the NovaSeq announcement. Schenkel, who believes there is an upward bias to revenue forecasts for 2018 and 2019, reiterated his Outperform rating on Illumina shares.
02/07/17
COWN
02/07/17
NO CHANGE
Target $17
COWN
Outperform
GenMark concern surrounding NeoPrep discontinuation overblown, says Cowen
Cowen analyst Doug Schenkel noted GenMark (GNMK) shares have declined 10% year-to-date, which he attributes to concerns surrounding Illumina's (ILMN) decision to discontinue NeoPrep. The analyst believes these concerns are overblown as the company has entered into an amended supply agreement, which was confirmed in their 10-Q. Schenkel maintained his Outperform rating and $17 price target on GenMark shares.
01/18/17
DBAB
01/18/17
INITIATION
Target $160
DBAB
Hold
Illumina initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Dan Leonard started Illumina with a Hold rating and $160 price target.
02/27/17
EVER
02/27/17
UPGRADE
EVER
Buy
Illumina upgraded to Buy from Hold at Evercore ISI
Evercore ISI analyst Ross Muken to Buy with a $190 price target following customer checks that lead him to above consensus revenue forecasts. Muken believes Illumina will sell 750-1,300 NovaSeq boxes over the next several years as sequencing enters a new era of utility. He sees an expansion in the sequencing landscape given Nova's application flexibility and believes it addresses capacity utilization challenges. Muken's forecast is now above consensus and expects performance to accelerate into 2H revenue beats and a solid pathway into 2018.
CCL Carnival
$55.97

-0.06 (-0.11%)

02/27/17
ARGS
02/27/17
UPGRADE
ARGS
Buy
Carnival upgraded on demand outlook at Argus
As noted earlier, Argus upgraded Carnival to Buy from Hold. Analyst John Staszak says that he now believes that "continued " improvement in demand for cruises will improve the company's earnings and margins. Target $64.
02/27/17
ARGS
02/27/17
UPGRADE
ARGS
Buy
Carnival upgraded to Buy from Hold at Argus
02/23/17
FBCO
02/23/17
NO CHANGE
Target $67
FBCO
Outperform
Carnival price target raised to $67 from $60 at Credit Suisse
Credit Suisse analyst Tim Ramskill raised his price target for Carnival to $67 from $60 as yield momentum, cost discipline and excess cash returns outweigh supply. The analyst reiterates an Outperform rating on the shares.
01/06/17
BERN
01/06/17
NO CHANGE
Target $63
BERN
Outperform
Carnival OCEAN platform to be 'powerful competitive advantage,' says Bernstein
Bernstein analyst David Beckel said Carnival's OCEAN "connected experience" platform, unveiled at CES 2017, could, and likely will, be emulated to some extent across the entire travel industry. However, citing Carnival's head start, scale, and technology expertise, he sees OCEAN becoming a "powerful competitive advantage for the company for years to come." Beckel keeps his Outperform rating and $63 price target on Carnival shares.
CEMP Cempra
$4.05

0.9 (28.57%)

02/27/17
02/27/17
UPGRADE
Target $8

Buy
Cempra upgraded to Buy at Roth Capital
As previously reported, Roth Capital analyst Michael Higgins upgraded Cempra to Buy from Neutral after the company announced positive Phase 3 results in the first of two skin infection studies with Taksta, and ahead of bone data in 2017. The analyst also raised his price target on the shares to $8 from $2.50.
02/27/17
JANY
02/27/17
NO CHANGE
Target $8
JANY
Neutral
Cempra price target lowered to $8 from $10 at Janney Capital
Janney Capital analyst Debjit Chattopadhyay said the release of data from the phase 3 ABSSI study of fusidic acid "provides a lifeline" for Cempra, though he sees limited differentiation in a crowded segment where the drug would have to compete against generics. The analyst, who thinks the best course forward would be give up on SoliThera in the U.S., "hope for a positive take from the EMA," and consider strategic alternatives, keeps a Neutral rating on Cempra shares and lowered his fair value estimate on the stock to $8 from $10.
01/12/17
JPMS
01/12/17
NO CHANGE
JPMS
Neutral
Cempra may not run FDA requested safety study for solithromycin, says JPMorgan
In a recap of the presentation made by Cempra at the JPMorgan Healthcare conference, JPMorgan analyst Jessica Fye noted that in the presentation and following breakout session, management said they are reluctant to run a multi-thousand patient safety study that would likely be required for approval of solithromycin for treatment of Community-Acquired Bacterial Pneumonia. However, the company announced the accelerated evaluation of soli into the ophthalmic antibiotic market and plans to meet with the FDA to discuss this potential, added Fye. She keeps a Neutral rating on Cempra shares, as she sees the company in a challenging position with CABP approval "appearing off the table."
02/27/17
ROTH
02/27/17
UPGRADE
ROTH
Buy
Cempra upgraded to Buy from Neutral at Roth Capital
UN Unilever; also tag UL
$47.36

0.45 (0.96%)

02/23/17
SOCG
02/23/17
UPGRADE
SOCG
Buy
Unilever upgraded to Buy from Hold at Societe Generale
Societe Generale analyst Warren Ackerman upgraded Unilever to Buy and raised his price target for the shares to EUR 50 from EUR 42.
02/22/17
RBCM
02/22/17
NO CHANGE
RBCM
Edgewell the most likely takeover target in HPC, says RBC Capital
RBC Capital analyst Nik Modi says that Edgewell (EPC) is the most likely takeover target in the household and personal care space. He sees some parallels between Edgewell and Gillette in 2004. In that year Gilette launched a cost cutting initiative which doubled its profit per employee and raised its EBIT margin by over five percentage points, according to the analyst. Additionally, Modi says that a larger, multi-national company could bring the products of Edgewell's Schick unit to many more markets. Given the multiple problems with Unilever's (UL,UN) Dollar Shave Club, Unilever "is a leading suitor for Edgewell," according to Modi.
02/21/17
FBCO
02/21/17
NO CHANGE
Target $100
FBCO
Outperform
Kraft Heinz price target raised to $100 from $95 at Credit Suisse
Credit Suisse analyst Robert Moskow raised his price target for Kraft Heinz (KHC) to $100 from $95 on valuation. After Unilever (UN; UL) rejected Kraft Heinz's offer to acquire the company for $50 per share, the analyst believes Kraft Heinz will come back with a higher and formal bid of at least $53 per share. He reiterates an Outperform rating on Kraft Heinz's shares.
02/27/17
BOFA
02/27/17
UPGRADE
BOFA
Neutral
Unilever upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst David Hayes upgraded Unilever to Neutral and increased the target price to $45 from $35 due to valuation and believes the strategic review could accelerate margin development targets over the next 4 years.
UL Unilever; also tag UN
$47.52

0.4 (0.85%)

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

12:17
03/23/17
03/23
12:17
03/23/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TISA

Top Image Systems

$1.24

-0.0212 (-1.68%)

12:16
03/23/17
03/23
12:16
03/23/17
12:16
Hot Stocks
Breaking Hot Stocks news story on Top Image Systems »

Palogic Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
03/23/17
03/23
12:16
03/23/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
03/23/17
03/23
12:15
03/23/17
12:15
General news
Treasury Action: bonds are in limbo awaiting results the House ACA vote »

Treasury Action: bonds…

12:15
03/23/17
03/23
12:15
03/23/17
12:15
General news
Breaking General news story  »

Minneapolis Federal…

Z

Zillow

$35.29

0.12 (0.34%)

12:11
03/23/17
03/23
12:11
03/23/17
12:11
Options
Bearish flow in Zillow as shares falter »

Bearish flow in Zillow as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

12:10
03/23/17
03/23
12:10
03/23/17
12:10
General news
U.S. equities are dusting themselves off »

U.S. equities are dusting…

ATEC

Alphatec

$2.68

-0.12 (-4.29%)

12:08
03/23/17
03/23
12:08
03/23/17
12:08
Syndicate
Alphatec announces $18.9M private placement »

H.C. Wainwright is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OA

Orbital ATK

$99.47

-0.075 (-0.08%)

12:08
03/23/17
03/23
12:08
03/23/17
12:08
Periodicals
SSL sues Orbital ATK over claims of confidential data theft, Reuters says »

Space Systems/Loral has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

TRIP

TripAdvisor

$41.40

-0.31 (-0.74%)

, PCLN

Priceline

$1,751.99

4.85 (0.28%)

12:06
03/23/17
03/23
12:06
03/23/17
12:06
Hot Stocks
TripAdvisor strength attributed to takeover speculation »

The intraday move up in…

TRIP

TripAdvisor

$41.40

-0.31 (-0.74%)

PCLN

Priceline

$1,751.99

4.85 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:01
03/23/17
03/23
12:01
03/23/17
12:01
Conference/Events
Stephens transportation analysts hold an analyst/industry conference call »

Transportation Analysts…

BAC

Bank of America

$23.34

0.4 (1.74%)

12:01
03/23/17
03/23
12:01
03/23/17
12:01
Options
Today's four most active single stock options are calls on BofA »

Today's four most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$270.93

1.51 (0.56%)

12:01
03/23/17
03/23
12:01
03/23/17
12:01
Hot Stocks
Lockheed Martin to expand production for F-35 components in Johnstown »

Lockheed Martin will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

CEO

CNOOC

$118.68

3.25 (2.82%)

11:59
03/23/17
03/23
11:59
03/23/17
11:59
Upgrade
CNOOC rating change  »

CNOOC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POL

PolyOne

$33.38

0.47 (1.43%)

11:59
03/23/17
03/23
11:59
03/23/17
11:59
Conference/Events
PolyOne management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

  • 27

    Mar

GRBK

Green Brick

11:56
03/23/17
03/23
11:56
03/23/17
11:56
Hot Stocks
Green Brick Partners director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLXN

Flexion

$19.68

0.14 (0.72%)

, SNY

Sanofi

$45.09

0.42 (0.94%)

11:56
03/23/17
03/23
11:56
03/23/17
11:56
Recommendations
Flexion, Sanofi analyst commentary  »

Flexion CFO departure…

FLXN

Flexion

$19.68

0.14 (0.72%)

SNY

Sanofi

$45.09

0.42 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 10

    May

  • 06

    Oct

SAN

Banco Santander

$6.12

0.005 (0.08%)

11:55
03/23/17
03/23
11:55
03/23/17
11:55
Hot Stocks
Santander to improve consumer protections in Fed agreement »

Santander has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
03/23/17
03/23
11:55
03/23/17
11:55
Conference/Events
Federal Reserve Bank of Minneapolis President speaks at conference »

Minneapolis Federal…

MAA

MAA

$101.99

0.72 (0.71%)

11:54
03/23/17
03/23
11:54
03/23/17
11:54
Conference/Events
MAA management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

ADP

ADP

$103.68

0.56 (0.54%)

, CSOD

Cornerstone OnDemand

$38.36

-0.14 (-0.36%)

11:53
03/23/17
03/23
11:53
03/23/17
11:53
Conference/Events
Stephens enterprise software analysts hold an analyst/industry conference call »

Enterprise Software…

ADP

ADP

$103.68

0.56 (0.54%)

CSOD

Cornerstone OnDemand

$38.36

-0.14 (-0.36%)

ORCL

Oracle

$44.97

0.175 (0.39%)

PAYC

Paycom

$54.22

-1.06 (-1.92%)

PCTY

Paylocity

$35.16

-0.16 (-0.45%)

SAP

SAP

$98.09

0.44 (0.45%)

ULTI

Ultimate Software

$193.35

1.24 (0.65%)

WDAY

Workday

$81.64

0.19 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 09

    May

  • 08

    Jun

  • 20

    Jun

TRP

TransCanada

$46.42

0.25 (0.54%)

11:52
03/23/17
03/23
11:52
03/23/17
11:52
Periodicals
State Department expected to approve Keystone XL pipeline permit, Politico says »

The U.S. State Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$10.02

-0.1 (-0.99%)

11:51
03/23/17
03/23
11:51
03/23/17
11:51
Options
Vote of confidence in the US Oil Fund »

Vote of confidence in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$108.45

2.36 (2.22%)

11:45
03/23/17
03/23
11:45
03/23/17
11:45
Periodicals
Alibaba looking to move beyond China, Nikkei says »

Alibaba is looking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:45
03/23/17
03/23
11:45
03/23/17
11:45
General news
Breaking General news story  »

Minneapolis Federal…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.